Table 3.
Average resource use for rehabilitation and outpatient medication use during one year follow up by treatment group
| Resource | Average resource use (days) | Unit costs (£/day) | Costs (£) | ||
| PCI (n = 488) | CABG (n = 500) | PCI (n = 488) | CABG (n = 500) | ||
| Rehabilitation | |||||
| Other hospital for rehabilitation or further treatment | 0.819 | 2.321 | 175 | 143.3 | 406.1 |
| Residential or nursing home care on a temporary basis | 0.029 | 0.042 | 53.97 | 1.5 | 2.3 |
| Medication | |||||
| Antiplatelet | |||||
| Aspirin | 347.72 | 332.08 | 0.05 | 17.40 | 16.60 |
| Ticlopidine | 81.72 | 20.13 | 3.34 | 272.94 | 67.23 |
| Other (clopidogrel) | 20.86 | 3.79 | 0.59 | 12.31 | 2.24 |
| Other (dipyridamole) | 0.20 | 7.02 | 0.11 | 0.02 | 0.77 |
| Anticoagulants | |||||
| Warfarin | 4.18 | 11.34 | 0.11 | 0.46 | 1.25 |
| Heparin | 0 | 1.84 | 3.44 | 0 | 6.33 |
| Low molecular weight heparin (dalteparin sodium) | 4.78 | 2.42 | 11.30 | 54.01 | 27.35 |
| Antianginal agents | |||||
| β Blockers (atenolol) | 215.30 | 178.24 | 0.03 | 6.46 | 5.35 |
| Calcium channel antagonists (diltiazem) | 132.65 | 75.76 | 0.30 | 39.80 | 22.73 |
| Nitrates (isosorbide mononitrate) | 151.20 | 53.75 | 0.40 | 60.48 | 21.50 |
| Potassium channel activators (nicorandil) | 9.93 | 1.39 | 0.26 | 2.58 | 0.36 |
| Lipid lowering agents | |||||
| Fibrates (bezafibrate) | 23.94 | 19.57 | 0.20 | 4.79 | 3.91 |
| HMG-CoA reductase inhibitors (simvastatin) | 231.41 | 194.02 | 1.06 | 245.29 | 205.66 |
| Other (nicotinic acid) | 1.16 | 0 | 1.11 | 1.29 | 0 |
| Other cardiac treatment | |||||
| ACE inhibitor (lisinopril) | 113.52 | 89.59 | 0.65 | 73.79 | 58.23 |
| Diuretics (furosemide) | 56.56 | 93.19 | 0.08 | 4.52 | 7.46 |
| Digoxin | 6.61 | 15.13 | 0.02 | 0.13 | 0.30 |
| Antiarrhythmic (amiodarone) | 6.62 | 12.24 | 0.23 | 1.52 | 2.82 |
| Antiarrhythmic (propafenone) | 0.42 | 1.88 | 0.71 | 0.30 | 1.33 |
| Antiarrhythmic—β blocker (sotalol hydrochloride) | 0.79 | 1.01 | 0.18 | 0.14 | 0.18 |
| Antiarrhythmic—calcium channel antagonist (verapamil) | 0.65 | 0 | 0.30 | 0.20 | 0 |
| Other cardiac agents | |||||
| Antihypertensive (clonidine hydrochloride) | 0.31 | 0 | 0.17 | 0.05 | 0 |
| α Adrenoceptor blocker (doxazosin) | 3.63 | 0.88 | 0.63 | 2.29 | 0.55 |
| α Adrenoceptor blocker (indoramin) | 0 | 0.15 | 0.40 | 0 | 0.06 |
| Angiotensin II antagonist (candesartan cilexetil) | 2.54 | 2.06 | 0.53 | 1.35 | 1.09 |
| Angiotensin II antagonist (irbesartan) | 0.36 | 1.04 | 0.59 | 0.21 | 0.61 |
| Angiotensin II antagonist (losartan potassium) | 2.34 | 1.69 | 0.62 | 1.45 | 1.05 |
| Angiotensin II antagonist (valsartan) | 0.72 | 0 | 0.56 | 0.40 | 0 |
ACE, angiotensin converting enzyme; HMG-CoA, hydroxymethyl glutaryl coenzyme A.